Table 1

The levels of RANTES and β-TG in plasma and platelets in patients with breast and cervical cancers according to clinical stage and in progression or in remissiona

SubjectsStagePlasma RANTESPlatelet RANTES pg/106 platelets mean ± SDPlasma β-TG IU/ml mean ± SDPlatelet β-TG IU/106 platelets mean ± SD
pg/ml mean ± SDNo. of cases with RANTES levels
>10,000<4000
Breast cancer patients (43)I (5)2,781 ± 315041,706 ± 1831,196 ± 104136 ± 12
II (11)4,263 ± 604b151,498 ± 124b1,251 ± 106124 ± 11
III (12)7,489 ± 1,234c251,409 ± 128b1,395 ± 120b108 ± 12b
IV (15)8,769 ± 1,527c481,112 ± 126b1,496 ± 138c98 ± 11b
Cervical cancer patients (23)I (3)2,743 ± 306021,698 ± 1761,203 ± 116137 ± 10
II (4)3,929 ± 346221,550 ± 1621,229 ± 121126 ± 13
III (6)7,046 ± 1,149c231,369 ± 115b1,346 ± 113b114 ± 13b
IV (10)8,272 ± 1,564c351,204 ± 141b1,428 ± 145c108 ± 11b
Patients with breast and cervical cancers (66)Progressive (45)8,472 ± 1,432c12221,125 ± 138b1,462 ± 130c103 ± 12b
In remission (21)4,123 ± 623b2121,684 ± 181b1,114 ± 112128 ± 12
Healthy volunteers (12)2,916 ± 348281,866 ± 175909 ± 82140 ± 12
  • a Parentheses denotes the number of the cases tested.

  • b 0.01 < P < 0.05 versus healthy volunteers.

  • c P < 0.01.